发明名称 METHOD FOR PR-39 PEPTIDE MEDIATED SELECTIVE INHIBITION OF I kappa B alpha DEGRADATION
摘要 The present invention provides both a method and means for regulating I kappa B alpha degradation, NF kappa B activity, and NF kappa B-dependent gene expression within living cells, tissues, and organs in-situ. The selective regulation is performed using native PR-39 peptide or one of its shorter-length homologs, for interaction with such I kappa B alpha and proteasomes as are present in the cytoplasm of viable cells. The result of PR-39 peptide interaction with I kappa B alpha is a selective alteration in the intracellular proteolytic activity of proteasomes, which in turn, causes a reduction of I kappa B alpha , a decrease of NF kappa B activity, and a down-regulation of NF kappa B-dependent gene expression.
申请公布号 WO0147540(A1) 申请公布日期 2001.07.05
申请号 WO2000US35293 申请日期 2000.12.27
申请人 BETH ISRAEL DEACONESS MEDICAL CENTER 发明人 SIMONS, MICHAEL;GAO, YOUHE
分类号 A61K38/00;C07K14/47;(IPC1-7):A61K38/00;A61K38/16;C07K7/00;C07K7/04;C07K7/06 主分类号 A61K38/00
代理机构 代理人
主权项
地址